Oncology KnowledgeBASE

  • ID: 4419864
  • Newsletter
  • New MEdicine Inc
1 of 4
A Dynamic, Daily Updated, Full Relational, User-Friendly, Comprehensive Resource in Global Drug Development in Oncology


  • BridgeBio Pharma
  • CureVac
  • Gilead Sciences
  • immatics Biotechnologies
  • Intezyne Technologies
  • Kitov Pharmaceuticals
  • MORE

Oncology KnowledgeBASE is a relational knowledgebase covering all major aspects of product development in oncology. The database comprises 6 modules each dedicated in a specific sector within the oncology field. Use the keyword option or the query screen within each module to find the data sought. Entries are cited with links to the origin of the data when appropriate. As a relational resource, Oncology KnowledgeBASE allows the user to retrieve comprehensive data along numerous lines of inquire as described below.

New and Marketed Drugs Module

These modules comprise comprehensive records of thousands of drugs in discovery/research, preclinical and clinical development and those on the market globally. Numerous possible inquiries within these modules include:

  • Individual company pipelines
  • Company affiliations
  • Marketed or novel drugs by target (and by indication, clinical status, technology, mechanism, delivery, etc.)
  • Marketed or novel drugs by mechanism (cytotoxics, immunotherapy agents, angiogenesis inhibitors, apoptosis enhancers, gene silencing agents, oncolytics, etc.)
  • Marketed or novel drugs by technology (small molecule drugs, monoclonal antibodies, antibody-drug conjugates, immune-oncology agents, fusion proteins, synthetic nucleic acid sequences and RNAi, radioimmunoconjugates, etc.)
  • Marketed or novel drugs by drug delivery (liposomes, nanoparticles, PEG, vectors, etc.)
  • Marketed or novel drugs by indication (100 different cancer indications and over 2000 clinical indications)
  • Novel drugs by phase of clinical development (clinical trials described for over 2000 novel agents, with interim and final results when appropriate)
  • Biomarkers associated with the development of new drugs (over 2,160 targeted drugs in clinical/preclinical development)
  • Marketed drugs by approved indication (over 530 branded drugs)

Company Module

This module profiles thousands of companies spanning the spectrum of small start-ups to multinational biotechnology and pharmaceutical companies developing drugs and personalized medicine tools or providing enabling technologies in this sector. Possible inquiries within these modules include:

  • Full address, list of company executives, website links, etc.
  • Financings, IPO, mergers and acquisitions
  • Descrition of enabling technologies
  • Affiliations and collaborations worldwide
  • Diagnostics/personalized medicine products and services by cancer indication (diagnostics, prognostics, theragnostics, disease monitoring methodologies, pharmacogenomics, etc.)

Targets in Oncology Module

This module profiles over 1000 molecular markers relevant in personalized medicine. Numerous possible inquiries within these modules include:

  • Marker profile (name, location, description,
  • Markers by cancer indication (over 100 indications)
  • Markers by expression site (secreted, cell membrane. intracellular, cytoplasm, nucleus, cytosol, etc.)
  • Markers incorporated in vitro testing (IVT) assays


This module includes reports covering unique aspects of the oncology sector often related to government, academic, or nonprofit activities that may impact the science and or delivery of cancer-related care.

The news summaries below pertain to the development and status of oncology-related drugs, noninvasive imaging agents, and in vitro tests. The information covers novel and marketed drugs, oncology targets and company profiles, including detailed descriptions of drug development technologies and in vitro testing methodologies and products.

New Drugs And Marketed Drugs
New Drugs

  • Itraconazole (Monday, October 30, 2017)
  • Seribantumab MM-121, MM121, SAR256212 (Monday, October 30, 2017)
  • Tinostamustine EDO-S101 (Monday, October 16, 2017)
  • Dacomitinib PF-299804, PF-00299804, PF-299,804, PF00299804 (Sunday, October 15, 2017)
  • Apalutamide ARN-509, JNJ-56021927 (Thursday, October 12, 2017)
  • STRO-001 (Wednesday, October 11, 2017)
  • PCM-075, formerly NMS-1286937 (Monday, October 9, 2017)
  • CAN04 (Monday, October 9, 2017)

Marketed Drugs

  • Imbruvica Ibrutinib (Oct-30-2017)
  • Keytruda Pembrolizumab (formerly lambrolizumab) (Oct-28-2017)
  • Avastin Bevacizumab (Oct-26-2017)
  • Kyprolis Carfilzomib (Oct-24-2017)
  • Yescarta Axicabtagene ciloleucel (Oct-19-2017)

Company, Targets and In Vitro Tests

  • OncoSec Medical (Oct-24-2017)
  • CureVac(Oct-20-2017)
  • Sutro Biopharma(Oct-11-2017)
  • Kitov Pharmaceuticals(Oct-10-2017)
  • MabVax Therapeutics(Oct-07-2017)
  • Intezyne Technologies(Oct-06-2017)
  • BridgeBio Pharma(Oct-05-2017)
  • Gilead Sciences(Oct-4-2017)
  • immatics Biotechnologies (Oct-03-2017)

Targets in Oncology

  • Phosphatase and tensin homolog (PTEN)/mutated in multiple advanced cancers 1 (MMAC1) (Oct-31-2017)
  • Nuclear receptor subfamily 0 group B member 1 (NR0B1) (Oct-22-2017)
  • DNA topoisomerase II alpha (TOP2A) (Oct-22-2017)
  • Axl (Oct-12-2017)

Special Reports
The Special Reports entries cover broad oncology-related topics involving activities by academic institutions, government agencies, companies, foundations, etc. Topics of these reports include novel findings in the prevention, diagnosis and treatment of cancer; new governmental regulations regarding drug approvals, insurance coverage, research funding, etc.; advances in enabling technologies impacting the management of patients with cancer; and other issues in oncology emanating from the non-commercial sector.

Special Reports

  • The Targeted Agent and Profiling Utilization Registry (TAPUR) Trial (Oct-31-2017)
  • Public-Private Consortium ATOM Aims to Speed Preclinical Cancer Drug Discovery (Oct-27-2017)
  • CancerLinQ-Analyzing Real-word Cancer Data (Aug-28-2017)
  • The Human Pathology Atlas-a Genome-wide Transcriptome of Key Human Malignancies (August 18, 2017)
Note: Product cover images may vary from those shown
2 of 4


3 of 4
  • BridgeBio Pharma
  • CureVac
  • Gilead Sciences
  • immatics Biotechnologies
  • Intezyne Technologies
  • Kitov Pharmaceuticals
  • MabVax Therapeutics
  • OncoSec Medical
  • Sutro Biopharma
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown